Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-blind, Phase III ENHANCE Trial of Prolonged-release Fampridine

Authors

Jeremy Hobart, Peninsula Medical School
Tjalf Ziemssen, Technische Universität Dresden
Peter Feys, Hasselt University
Michael Linnebank, Witten/Herdecke University
Andrew D. Goodman, University of Rochester
Rachel Farrell, University College London
Raymond Hupperts, Zuyderland
Andrew R. Blight, Acorda Therapeutics, Inc
Veronica Englishby, Biogen IDEC
Manjit McNeill, Biogen IDEC
Ih Chang, Biogen IDEC
Jacob Elkins, Biogen IDEC

ORCID

• Jeremy Hobart: 0000-0002-2114-7920

DOI Link

10.1007/s40263-018-0586-5

DOI

10.1007/s40263-018-0586-5

Publication Date

2019-01-01

Publication Title

CNS Drugs

Volume

33

Issue

1

ISSN

1172-7047

Embargo Period

2019-02-12

First Page

61

Last Page

79

Recommended Citation

Hobart, J., Ziemssen, T., Feys, P., Linnebank, M., Goodman, A., Farrell, R., Hupperts, R., Blight, A., Englishby, V., McNeill, M., Chang, I., & Elkins, J. (2019) 'Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-blind, Phase III ENHANCE Trial of Prolonged-release Fampridine', CNS Drugs, 33(1), pp. 61-79. Available at: 10.1007/s40263-018-0586-5